Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19
A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in the Treatment of Patients With Hematological Disorders Who Are Persistently Positive for the Covid-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Beijing Boren Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects in this study must meet all of the following criteria:
- Male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment;
- On the day of enrollment, the subject was judged to be positive for Covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days;
- On the day of enrollment, patients who have received CAR T-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood B cells is less than 2%;
- Subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs;
- Subjects voluntarily participate in the trial and sign the informed consent form before the study begins.
Exclusion Criteria:
Those who meet any of the following conditions will be excluded:
- Those who are known to be allergic to the test drug and any component in the preparation, or other similar drugs;
- Complications requiring surgery within 7 days, or complication considered life-threatening within 28 days;
- Received treatment with SARS-CoV-2 neutralizing antibody drugs before screening;
- Convalescent plasma from recovered patients before screening;
- Patients who took anti-SARS-CoV-2 drugs within 48 hours before enrollment, including but not limited to Paxlovid (Nirmatrelvir/Ritonavir), Azvudine, Molnupiravir, etc.
- On the day of enrollment, meet the diagnostic criteria for severe/critical new coronavirus pneumonia;
- Suspected to have been combined with active bacteria, fungi, viruses or other infections other than the new coronavirus;
- Those who plan to become pregnant, are pregnant, or are breastfeeding;
- Participated in clinical trials of SARS-CoV-2 neutralizing antibody drugs within 180 days before screening or participated in clinical trials of other drugs or medical devices within 4 weeks before screening;
- Suffering from severe neurological diseases (epilepsy, convulsions or convulsions) or mental illness, with a family history of mental illness;
- Suffering from other serious diseases that are not controlled, such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine system diseases; or other diseases that the researchers judge are not suitable for participating in the study (such as currently uncontrolled autoimmune diseases, etc. );
- Other conditions that the researcher believes are not suitable for participating in this study due to various reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Anti-COVID-19 Antibody SA55 for Injection
|
After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
|
|
Placebo Comparator: Placebo
Anti-COVID-19 Antibody SA55 for Injection administered intramuscular
|
After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time when the subject has nucleic acid and the antigen test continues to turn negative
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of Subjects Progressing to Severe/Critical
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects who died from any cause
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects admitted to ICU
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Number of days a case was admitted to the ICU
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects with severe/critical illness or all-cause death related to COVID-19
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
The incidence of AEs
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
The incidence of SAEs
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Time of subject's shock correction
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects requiring oxygen therapy
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects requiring non-invasive ventilation
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of subjects requiring mechanical ventilation
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Days of subject's hospitalization from dosing
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Change of CT value
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
|
Proportion of patients with negative persistent nucleic acid test(NAT)(key secondary endpoint)
Time Frame: 21 days post intramuscular injection
|
21 days post intramuscular injection
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia, Viral
- Pneumonia
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- COVID-19
- Hematologic Diseases
- Immunologic Factors
- Physiological Effects of Drugs
- Antibodies
Other Study ID Numbers
Other Study ID Numbers
- PRO-SA55-0004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.